- Home
- SPCE vs SGMT Comparison
SPCE vs SGMT Comparison
Compare SPCE & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- SGMT
- Stock Information
- Founded
- SPCE 2017
- SGMT 2006
- Country
- SPCE United States
- SGMT United States
- Employees
- SPCE N/A
- SGMT N/A
- Industry
- SPCE Transportation Services
- SGMT
- Sector
- SPCE Consumer Discretionary
- SGMT
- Exchange
- SPCE Nasdaq
- SGMT Nasdaq
- Market Cap
- SPCE 226.9M
- SGMT 238.7M
- IPO Year
- SPCE N/A
- SGMT 2023
- Fundamental
- Price
- SPCE $3.61
- SGMT $7.73
- Analyst Decision
- SPCE Hold
- SGMT Strong Buy
- Analyst Count
- SPCE 5
- SGMT 8
- Target Price
- SPCE $10.60
- SGMT $26.88
- AVG Volume (30 Days)
- SPCE 4.9M
- SGMT 601.1K
- Earning Date
- SPCE 11-13-2025
- SGMT 11-13-2025
- Dividend Yield
- SPCE N/A
- SGMT N/A
- EPS Growth
- SPCE N/A
- SGMT N/A
- EPS
- SPCE N/A
- SGMT N/A
- Revenue
- SPCE $1,698,000.00
- SGMT N/A
- Revenue This Year
- SPCE N/A
- SGMT N/A
- Revenue Next Year
- SPCE $2,908.26
- SGMT N/A
- P/E Ratio
- SPCE N/A
- SGMT N/A
- Revenue Growth
- SPCE N/A
- SGMT N/A
- 52 Week Low
- SPCE $2.18
- SGMT $1.73
- 52 Week High
- SPCE $8.19
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- SPCE 44.01
- SGMT 50.06
- Support Level
- SPCE $3.47
- SGMT $7.53
- Resistance Level
- SPCE $3.73
- SGMT $8.62
- Average True Range (ATR)
- SPCE 0.25
- SGMT 0.64
- MACD
- SPCE -0.08
- SGMT -0.05
- Stochastic Oscillator
- SPCE 20.37
- SGMT 24.54
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.